IHC is also the standard of care utilised by the AJCC in determining the presence of HPV in patients with OPSCC. 9 Other techniques for HPV testing including the sensitivity and specificity of these tests are described in Table 1 .
Human papilloma virus testing for OPSCC is typically performed on surgically obtained biopsies performed under general anaesthesia or on core biopsies of suspected lymph node metastasis obtained under ultrasound guidance. These investigations have associated costs and risks including pain, bleeding, infection, dental injury, oesophageal perforation and rarely airway compromise. The procedures can result in delays to the patient pathway particularly when a diagnosis of squamous cell carcinoma is first made with fine-needle aspiration cytology (FNAC). In these cases, a supplementary surgical or core biopsy is needed from the primary site or nodal metastasis to confirm p16 status. With existing pressures on cancer diagnostic services, 11 the process from initial presentation to establishing the HPV status on a biopsy of a patient with OPSCC may take weeks.
Human papilloma virus is detectable in the saliva of patients with OPSCC using PCR. This non-invasive, relatively inexpensive test, without side-effects and taken at the point of first patient contact could allow for the HPV status of patients to be established much earlier. Salivary HPV testing has the potential to mitigate the need for invasive biopsies performed solely for the purpose of HPV detection and could form a routine part of screening and risk stratification in patients suspected of OPSCC. To our knowledge, there is no prospective diagnostic accuracy study directly comparing the efficacy of oral rinse testing to the clinically accepted standards of p16 IHC and DNA ISH in patients with OPSCC.
| AIMS
The aim of this study was to determine the sensitivity and specificity of oral rinse (OR) testing for HPV in patients with OPSCC.
| MATERIALS AND METHODS
A prospective diagnostic accuracy study estimating the sensitivity and specificity of oral rinse testing using PCR for HPV to p16 IHC and DNA ISH in patients with OPSCC was conducted. The study flow diagram is shown in Figure 1 . Both QUADAS-2 12 and STARD criteria 13 • The test is easily administered in a clinical setting with no associated adverse events.
• 
| Statistical analysis
A power calculation was conducted using StataCorp. 2013 (Stata Statistical Software: Release 13. College Station, TX: StataCorp LP) software to determine a sample size of 45 for 80% power to determine results with a standard error of 5% and 10% confidence intervals. All statistical analyses were predetermined and performed using Prism 6
for Mac OS X (© 1994-2015 GraphPad Software, Inc, La Jolla, California USA). The demographic differences in the patient population based on p16 IHC and "true vs false" OR results were analysed using a Fisher's exact test when categorical values were less than 5 and a chi-square test when they were greater than 5 or when there were more than 2 categories. A result was considered significant when P was ≤.05. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) and their 95% confidence intervals were calculated.
| RESULTS
The mean age of participants was 58.8 years (range; 37-80) (see Table 2 ). 
| Identification of HPV subtypes
Oral rinse testing using the Linear Array HPV Genotyping Test Kit (Roche ©) allows identification of up to 37 different HPV subtypes. Twenty-seven of 46 "oral rinse" tests were positive for HPV (see Figure 3 ). 
| Evaluating potential confounding factors
To evaluate potential patient demographic, tumour or environmental factors that may have resulted in a false test result, additional patient-specific information was collected including time of last alcoholic drink, smoke, meal and exercise (see Table 4 ). Using the reference standard of combined p16 IHC and HPV DNA ISH as previously described, there were 35 patients (76.1%) with a true positive or negative result and 11 (23.9%) with a false-positive or false-negative result. There was no statistically significant difference between the two groups in terms of age, co-morbidities, T/N/M stage, last meal/smoke/alcohol or exercise.
| Adequacy of samples and adverse events
One (2.1%) of 47 oral rinse tests failed to provide a result despite confirming adequacy of DNA and repetition; the cause for this remains unclear. Whilst some patients reported that the taste of sodium chloride was unpleasant and some needed to repeat the test due to spillage, there were no adverse events associated with oral rinse testing.
| DISCUSSION
Our study has demonstrated that OR testing using PCR to detect The sensitivity of salivary testing however has been questioned with some authors reporting an inability to detect HPV from OR specimens in patients with known HPV+ve OPSCC. 19 Zhao et al. 20 detected HPV in 50% (21 of 42 specimens) of salivary samples from patients with HPV+ve OPSCC using PCR, whilst Wang et al. 21 found that saliva was inferior to plasma when testing for HPV in patients with OPSCC. They detected HPV in 40% of their salivary specimens and 86% of their plasma specimens. Our results contradict these findings; whilst plasma testing for HPV was not performed, we were able to detect HPV in the saliva of HPV+ve cases in 72.2% of cases.
This could relate to the way samples were collected, processed and stored in the studies.
Although the results of our study, which to our knowledge is the first of its kind, are promising, it is important to consider the results of PCR testing for HPV using other non-invasive biopsies. Channir et al. 22 There is a need for large prospective studies that look not only at the diagnostic accuracy of HPV detection in OPSCC but also at recurrence and the role of HPV testing in surveillance. It may be that OR testing alone may not be sufficient and require combination with other non-invasive tests. Ahn et al. 27 recently tested both saliva and serum to detect HPV in recurrent OPSCC with >90% specificity and 69.5% sensitivity. Future studies should compare all non-invasive diagnostic materials for HPV including brush cytology, FNA and serum plasma to both clinical and research standards for HPV detection, for example DNA ISH, RNA ISH, p16IHC and HPV DNA PCR.
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